MODERN STRATEGY IN TREATMENT OF PERITONEAL CARCINOMATOSIS

Peritoneal carcinomatosis (PC) is a common manifestation of progression in peritoneal and gynecologic malignancies. Current primary strategy in treatment of PC is the concept of regional influence by the way of cytoreductive surgery and intraperitoneal chemotherapy, which has proven the efficiency in treatment of common appendicitis tumors, peritoneum mesothelioma, advanced colorectal cancer, ovarian and gastric cancers. However, in spite of the existing unified criteria for performing cytoreductive surgeries, we observe a lack of a standardized approach for intra-peritoneal chemotherapy, which is used in various variants and regimens in modern clinical practice. Further studies of effectiveness of various intra-peritoneal chemotherapy methods and their combinations are necessary for the development of modern algorithms in treatment of PC.

1. Segelman J., Granath F., Holm T. et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer // Br. Journ. of Surgery. – 2012. – No 99. – Р. 699–705.

2. Isobe Y., Nashimoto A., Akazawa K. et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry // Gastric Cancer. – 2011. – No 14 (4). – Р. 301–316.

3. Fagotti A., Gallotta V., Romano F. et al. Peritoneal carcinosis of ovarian origin // World J. Gastrointest. Oncol. – 2010. – No 2 (2). – Р. 102–108.

4. Koh J. L., Tristan D. Y., Glenn D. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis // Ann Surg. Oncol. – 2009. – No 16. – Р. 327–333.

5. Rangole Ashvin & Jain Nikhilesh1. Preoperative Preparation and Patient Selection for Cytoreductive Surgery and HIPEC // Indian J. Surg. Oncol. – 2016. – No 7 (2). – Р. 208–214.

6. Van der Speeten K., Stuart O. A., Sugarbaker P. H. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy // Surgical oncology clinics of North America. – 2012. – № 21 (4). – Р. 577–597.

7. Saltz L. B., Clarke S. , Dнaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study // J. Clin. Oncol. – 2008. – No 26 (12). – Р. 2013–2019.

8. Sugarbaker P. H. Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction // Indian J. Surg. Oncol. – 2016. – No 7 (3). – Р. 295–302.

9. Verwaal V. J., Bruin S., Boot H. et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer // Annals of surgical oncology. – 2008. – No 15 (9). – Р. 2426–2432.

10. Verwaal V. J., van Ruth S., de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer // Journal of clinical oncology: official journal of the American Society of Clinical Oncology. – 2003. – No 21 (20). – Р. 3737–3743.

11. Baratti D., Kusamura S., Cabras A. D. et al. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) // Eur. journal of cancer (Oxford, England: 1990). – 2013. – No 49 (15). – Р. 3140–3148.

12. Spiliotis J., Halkia E., Lianos E. et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a pros pective randomized phase III study // Annals of surgical on co logy. – 2015. – No 22 (5). – Р. 1570–1575.

13. Marcotte E., Dube P., Drolet P. et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis // World J. Surg. Oncol. – 2014. – No 12. – Р. 332.

14. Sideris L., Mitchell A., Drolet P. et al. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix // Can. J. Surg. – 2009. – No 52 (2). – Р. 135–141.

15. Yan T. D., Deraco M., Baratti D. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience // Journal of clinical oncology: official journal of the American Society of Clinical Oncology. – 2009. – No 27 (36). – Р. 6237–6242.

16. Yonemura Y., Canbay E., Li Y. et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent // Eur. J. Surg. Oncol. – 2016. – No 42 (8). – Р. 1123–1131.

17. Glehen O., Gilly F. N., Arvieux C. et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy // Annals of surgical oncology. – 2010. – No 17 (9). – Р. 2370–2377.

18. Sugarbaker P. H. Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy: Textbook and Video Atlas. – 2012. – 214 p.

19. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent / L. De Smet, W. Ceelen, J. P. Remon, C. Vervaet // The Scientific World Journal. – 2013. – No 2013. – P. 720–858.

20. Dakwar G. R., Shariati M., Willaert W. et al. Nanomedicinebased intraperitoneal therapy for the treatment of peritoneal carcinomatosis – Mission possible? // Adv. Drug Deliv. Rev. – 2016.

21. Bakrin N., Bereder J. M., Decullier E. Peritoneal carcinomatosis treated with cytoreductive surgery and Hy perthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicenter retrospective cohort study of 566 patients // Eur. J. Surg. Oncol. – 2013. – No 39. – P. 1435–1443.

22. De Somer F., Ceelen W., Delanghe J. et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are asso ciated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin // Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis. – 2008. – No 28 (1). – Р. 61–66.

23. Van der Speeten K., Stuart O. A., Sugarbaker P. H. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy // Surgical oncology clinics of North America. – 2012. – No 21 (4). – Р. 577–597.

24. Sugarbaker P. H., Graves T., DeBruijn E. A. et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastro intestinal cancer: pharmacological studies // Cancer research. – 1990. – No 50 (18). – Р. 5790–5794.

25. Conti M., De Giorgi U., Tazzari V. et al. Clinical pharmacology of intraperitoneal cisplatin-based chemothe rapy // Journal of chemotherapy (Florence, Italy). – 2004. – No 16 (5). – Р. 23–25.

26. Van der Speeten K., Stuart O. A., Mahteme H., Sugarbaker P. H. Pharmacokinetic study of perioperative intravenous Ifosfamide // Int. journ. of surgical oncology. – 2011. – No 2011. – P. 185–192.

27. Glehen O., Osinsky D., Cotte E. et al. Intraperitoneal chemo hyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures // Ann. Surg. Oncol. – 2003. – No 10. – P. 863–869.

28. Boerner T., Graichen A., Jeiter T. et al. CRSHIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer // Ann. Surg. Oncol. – 2016. – No 23. – P. 3972–3977.

29. Yonemura Y., Endou Y., Sasaki T. et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer // Eur. J. Surg. Oncol. – 2010. – No 36. – P. 1131–1138.

30. Yang X. J., Li Y., Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric can cer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center // J. Surg. Oncol. – 2010. – No 101. – P. 457–464.

31. da Silva R. G., Sugarbaker P. H. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer // J. Am. Coll. Surg. – 2006. – № 203. – P. 878–886

32. Elias D., Mariani A., Cloutier A. S. et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin // Eur. J. Surg. Oncol. – 2014. – No 40. – P. 1467–1473.

33. Faron M., Macovei R., Goere D. et al. Linear relationship of peritoneal cancer index and survival in patients with pe ri toneal metastases from colorectal cancer // Ann. Surg. Oncol. – 2016. – No 23. – P. 114–119.

34. Zakharenko A. A., Natkha A. S., Belyaev M. A. et al. Experimental evidence for the most effective mode of aerosol laparoscopic intraperitoneal chemotherapy (PIPAC) // Oncology issues. – 2017. – No 63 (3). – Р. 490–496.

35. Bagnenko S. F., Zakharenko A. A., Nakhta A. S. et al. Clinical and experimental evidences of effective mode of aerosol laparoscopic intraperitoneal chemotherapy // Vestnik Khirurgii Imeni I. I. Grekova. – 2017. – No 176 (2). – Р. 95–99.

36. Solass W., Kerb R., Murdter T. Intraperitoneal chemo therapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy // Ann. Surg. Oncol. – 2014. – No 21. – P. 553–559.

37. Tempfer C. B., Solass W., Reymond M. A. Pressurized intra peritoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review // Wien Med Wochenschr. – 2014. – No 164 (23). – Р. 519–528.

38. Peritoneal sampling and histological assessmentof thera peutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS) // Pleura and Peritoneum. – 2016. – No 1 (2). – Р. 99–107.